Sarcoma – correlation between CD73 and PD-L1 and their relationship with prognosis

Abstract

This study aimed to evaluate CD73 and PD-L1 and determine their relationship with each other and with overall survival (OS) in sarcoma patients. The paraffin blocks of 101 patients were analysed. 56.4% were female, and the mean age was 51.39 years. The mean OS was 20.73 months, and the Ki-67 proliferative index was 41.45. A positive correlation was found between CD73 tumour and CD73 tumour-infiltrating lymphocyte (TIL) findings. CD73 tumour and TIL findings were also positively correlated with PD-L1 percentages and PD-L1 intensity. An inverse correlation was detected between OS and CD73 tumour and TIL groups of 5-25%, 25-50%, 50-75%, 75-90%, and > 90%, but no such correlation was found for the ≤ 5% group. There was an inverse correlation between OS and the PD-L1 percentages of <10% and > 50% and the PD-L1 intensity of weak-moderate and strong, but no correlation was found for the negative values. Lastly, an inverse correlation was found between OS and the Ki-67 proliferative index. We found CD73 and PD-L1 positivity to be associated with decreased OS in sarcoma patients and determined a significant correlation between these parameters. This result is promising in terms of achieving better survival and disease control with anti-CD73 and anti-PD-L1 therapy in selected patients.

Adenosine Increases the Immunosuppressive Capacity of Cervical Cancer Cells by Increasing PD-L1 Expression and TGF-β Production through Its Interaction with A2AR/A2BR

“…In this feedback loop, the production of Ado and the signaling of this nucleoside in cancer cells can promote the expression of PD-L1 through TGF-β production, consequently favoring immune evasion and tumor progression in CeCa. In this regard, the correlation between PD-L1 and CD73 has been related to cancer prognosis [ 63 , 64 ], and blocking CD73 and PD-L1 has been shown to promote the T-cell response [ 65 , 66 ]; hence, these results offer a promising therapeutic strategy for cancer. In addition, through the design of bispecific recognition proteins, the inhibition of both TGF-β and PD-L1 was recently proposed for the treatment of cancer [ 67 ].…”